Risk Of Developing Liver Cancer After HCV Treatment

Sunday, October 22, 2017

The Liver Meeting® - HCV direct acting antivirals: Generics shown to be bioequivalent to originator brands

On Twitter - Shared By Henry E. Chang

Follow "Henry E. Chang" on Twitter to review clinical research and updates from The Liver Meeting® 2017; online via an easy to view sharing platform.

Of Interest - Forging a Path to HCV Elimination

Bioequivalent pharmacokinetics for generic and originator HCV direct acting antivirals
Andrew M. Hill1, Loai Tahat2, Mohammed Khalil Mohammed3, Sanjay Nath4, Rabab Fayez Tayyem3, James A. Freeman5, Ismahane Benbitour7, Sherine Helmy

Conclusion 


Read More - https://jumpshare.com/v/XoSYlogQfKnr4rVRcUnt

Navigate This Blog 
The Liver Meeting® 2017

Patient-Friendly Links
Clinical Clips Each Day Of The Meeting
‘What you need to know in 5-minutes’
HCV Sites With Key Data, Expert Review & Summary

No comments:

Post a Comment